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Background: Genetic tests for hereditary hearing loss inform clinical management of patients and can provide the
first step in the development of therapeutics. However, comprehensive genetic tests for deafness genes by Sanger
sequencing is extremely expensive and time-consuming. Next-generation sequencing (NGS) technology is
advantageous for genetic diagnosis of heterogeneous diseases that involve numerous causative genes.
Methods: Genomic DNA samples from 58 subjects with hearing loss from 15 unrelated Japanese families were
subjected to NGS to identify the genetic causes of hearing loss. Subjects did not have pathogenic GJB2 mutations
(the gene most often associated with inherited hearing loss), mitochondrial m.1555A>G or 3243A>G mutations,
enlarged vestibular aqueduct, or auditory neuropathy. Clinical features of subjects were obtained from medical
records. Genomic DNA was subjected to a custom-designed SureSelect Target Enrichment System to capture
coding exons and proximal flanking intronic sequences of 84 genes responsible for nonsyndromic or syndromic
hearing loss, and DNA was sequenced by Illumina GAIIx (paired-end read). The sequences were mapped and
quality-checked using the programs BWA, Novoalign, Picard, and GATK, and analyzed by Avadis NGS.
Results: Candidate genes were identified in 7 of the 15 families. These genes were ACTG1, DFNA5, POU4F3, SLC26A5,
SIX1, MYO7A, CDH23, PCDH15, and USH2A, suggesting that a variety of genes underlie early-childhood hearing loss
in Japanese patients. Mutations in Usher syndrome-related genes were detected in three families, including one
double heterozygous mutation of CDH23 and PCDH15.
Conclusion: Targeted NGS analysis revealed a diverse spectrum of rare deafness genes in Japanese subjects and
underscores implications for efficient genetic testing.
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Hearing loss is a common sensory defect, affecting ap-
proximately one in 500 to 1000 newborns [1]. Approxi-
mately 50% of congenital hearing loss cases and 70% of
childhood hearing loss cases are attributed to genetic
mutations [1]. The remaining 50% of congenital cases* Correspondence: matsunagatatsuo@kankakuki.go.jp
†Equal contributors
1Laboratory of Auditory Disorders, National Institute of Sensory Organs,
National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka,
Meguro, Tokyo 152-8902, Japan
Full list of author information is available at the end of the article
© 2013 Mutai et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orare attributable to other factors such as prenatal exposure
to measles, cytomegalovirus, premature birth, and new-
born meningitis. Genetic tests for hereditary hearing loss
assist in the clinical management of patients and can pro-
vide the first step in the development of therapeutics [2].
For example, early diagnosis of Usher syndrome, which
comprises congenital hearing loss and late-onset retinitis
pigmentosa, provides important information to choose
communication modalities. However, causes of hereditary
hearing loss are highly heterogeneous; more than 60 genes
have been identified as responsible for nonsyndromictd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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diseases, such as Pendred syndrome and Usher syndrome,
are accompanied by hearing loss. GJB2 mutations are the
most common cause of childhood hearing loss worldwide
[1], followed by SLC26A4 mutations [4]. OTOF mutations
are common in patients with auditory neuropathy, which
is characterized by normal outer hair cell function and
abnormal neural conduction [5]. The prevalence of
childhood hearing loss patients with mutations in other
deafness-related genes is likely to be less than 1% [1].
Such high heterogeneity of hearing loss makes it im-
practical to perform genetic tests by Sanger sequencing.
This is also the case for some types of syndromic hear-
ing loss. For example, nine genes have been reported to
cause Usher syndrome, and all are large and difficult to
analyze using Sanger sequencing.
Next-generation sequencing (NGS) technology has been
applied to genetic diagnosis of nonsyndromic hearing loss
[6-8] and exploring the causes of hearing loss [9-11].
These studies have revealed that it is technically feasible
to identify causative genes for nonsyndromic and syn-
dromic hearing loss using targeted NGS [6,8]. In this
study, we used targeted NGS to identify the genetic
basis of hearing loss in Japanese families.
Methods
Subjects
This was a multi-center study of 58 subjects (36 subjects
with hearing loss and 22 subjects with normal hearing)
from 15 unrelated Japanese families in which at least
two family members had bilateral hearing loss. All sub-
jects were patients at the National Hospital Organization
Tokyo Medical Center or a collaborating hospital. Medical
histories were obtained and physical, audiological, and
radiological examinations were carried out for the subjects
and family members. Subjects with hearing loss related to
environmental factors were excluded. Subjects with GJB2
mutations or mitochondrial m.1555A>G or 3243A>G
mutations were excluded. Subjects with enlarged vestibu-
lar aqueduct, which is often associated with SLC26A4
mutations, and subjects with clinical features that sug-
gested syndromic hearing loss were excluded. Subjects
with auditory neuropathy were tested for OTOF muta-
tions, which are associated with auditory neuropathy
[12], and subjects with OTOF mutations were excluded.
The Ethics Review Committees of the National Hospital
Organization Tokyo Medical Center and all collaborat-
ing hospitals approved the study procedures. All proce-
dures were conducted after written informed consent
had been obtained from each subject or their parents.
Targeted capture and DNA sequencing
We selected coding exons and proximal flanking intronic
sequences of 84 genes, including 17 genes responsible forautosomal dominant nonsyndromic hearing loss (DFNA),
32 genes responsible for autosomal recessive nonsyn-
dromic hearing loss (DFNB), 8 genes responsible for
both DFNA and DFNB, one gene responsible for auditory
neuropathy, 3 genes responsible for X-linked hearing loss,
and 23 genes responsible for syndromic hearing loss. A
list of the targeted genes responsible for nonsyndromic
or syndromic hearing loss is provided in the supporting
material [Additional file 1]. More than 90% of the target
genomic sequences were successfully designed to be
captured by the SureSelect Target Enrichment System
(Agilent Technologies, CA, USA) (data not shown). Gen-
omic DNA was extracted from whole blood using the
Genetra Puregene DNA isolation kit (QIAGEN, Hilden,
Germany) and checked for quality using Qubit (Life tech-
nologies, CA, USA). Genomic DNA (3 μg) was fragmen-
ted into approximately 150 base pairs and used to
capture the targeted genomic sequences. The captured
DNA was subjected to the paired-end read sequencing
system (GAIIx system; Illumina, CA, USA).Sequence analysis
Sequence analysis initially focused on the 61 genes re-
sponsible for nonsyndromic hearing loss. If no candidate
mutations were detected among these genes, the 23 genes
responsible for syndromic hearing loss were subjected to
sequence analysis.
The sequences were mapped and quality-checked with
the programs BWA, Novoalign, Picard, and GATK using
the human reference sequence hg19/GRCh37. Single
and multiple nucleotide variants, including small inser-
tion or deletions that would affect amino acid sequences
or could affect splice sites, were annotated by Avadis
NGS v.1.4.5 (Strand Life Sciences, Bangalore, India). Vari-
ants already known as pathogenic mutations or detected
with <1% frequency in public databases (dbSNP135 [13],
1000GENOME [14], NHLBI Exome Variant Server [15])
were extracted and further subjected to segregation ana-
lysis within each family. If no candidate variants were
found, the 23 genes responsible for syndromic hearing loss
were subjected to the same procedures.
Selected variants were classified as known mutations,
possible pathogenic mutations, or variants with unknown
pathogenicity; the latter classification was made if there
were reports of a controversial finding of pathogenicity
or >1% allele frequency in the in-house database of
95 (up to 189) Japanese subjects with normal hearing.
Conservation of the corresponding mutated amino acid
was compared across nine primate, 20 mammal, and 13
vertebrate species by UCSC Conservation [16]. Functional
pathogenic effects of the variants were predicted by
PolyPhen-2 [17] and PROVEAN [18]. Effect on splice-site
mutations was predicted by NNSPLICE [19].
Mutai et al. Orphanet Journal of Rare Diseases 2013, 8:172 Page 3 of 11
http://www.ojrd.com/content/8/1/172All the variants and their segregation in each family
were confirmed by Sanger sequencing. The specific pri-
mer sets were selected from the resequencing amplicon
probe sets (NCBI) or designed originally by Primer-
BLAST (NCBI). The genotype of each individual and
segregation in the family was characterized using DNA-
SIS Pro (Hitachisoft, Tokyo, Japan).
Structural modeling
To find sequences homologous to ACTG1 and MYO7A
that could be used as the structural templates for the
modeling exercise, we searched the Protein Data Bank
(PDB) using Gapped BLAST [20] and PDBsum [21]. The
crystal structure of Limulus polyphemus filamentous actin
(PDB: 3B63) and the 4.1 protein-ezrin-radixin-moesin
(FERM) domain ofMus musculus myosin VIIa in complex
with Sans protein (PDB: 3PVL) were utilized as the
templates to model ACTG1 with the p.G268S mutation
and MYO7A with the p.W2160G mutation, respectively.
The models were built using SWISS-MODEL [22-24] inFigure 1 Pedigrees of the seven families with hearing loss. Double ho
genetic analysis by targeted next-generation sequencing. Single horizontal
Sanger sequencing. A-G denote pedigrees of family 1-7, respectively.the automatic modeling mode and with default param-
eters. The quality of the models was evaluated using
the Verify_3D Structure Evaluation Server [25,26]. The
α-carbon frames and ribbon models were superimposed
using Chimera [27].
Results
Pedigrees of the seven families are shown in Figure 1;
clinical features are described in Table 1 and supplemen-
tal materials [Additional file 2 and Additional file 3]. In
this targeted NGS study, the mean read depth of the tar-
get regions was more than 100× for all subjects (data
not shown). Table 2 summarizes the number of variants
detected from the 61 or 84 targeted genes for each
subject. The number of variants was consistent across
subjects (339–435 variants per subject for 61 genes,
539–607 variants per subject for 84 genes), which sup-
ported the reproducibility and reliability of our technical
procedures and analytical pipeline. After excluding fre-
quent variants (>1%) in public databases, 12 variants ofrizontal bars above a symbol indicate individuals who underwent
bars above a symbol indicate individuals who underwent analysis by
Table 1 Summary of subjects with hearing loss
Family Subject Age at onset (years) Age at the time of the study (years) Hearing loss severity (left/right)* Progression
1
III:3 45 53 Moderate/Moderate Yes
IV:2 10 16 Mild/Normal No
2
III:1 unknown no data Profound/Profound Unknown
III:2 unknown no data Moderate/Severe Unknown
IV:3 0 1 Severe** Yes
3
III:1 0 9 Severe** Unknown
III:2 0 6 Moderate/Moderate Unknown
4
I:2 0 30s Profound/Profound No
II:1 0 2 Profound/Profound No
5
III:1 0 2 Severe** No
III:2 0 2 Profound** No
6
II:1 5 14 Profound/Severe Yes
II:2 0 12 Profound/Profound Yes
7
II:1 0 3 Moderate (ASSR***) Unknown
II:2 0 0 Severe (ASSR) Unknown
*Hearing loss severity was evaluated based on average hearing level at 500, 1,000, 2,000, and 4,000 Hz (mild, 20–40 dB; moderate, 41–70 dB; severe, 71-95dB;
profound, >95 dB) according to recommendations [3]. **Binaural hearing level. ***ASSR, auditory steady state responses.
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as possible pathogenic mutations (Table 3) or variants
with uncertain pathogenicity in 7 families (Table 4).
Candidate mutations in each family
In family 1 (Figure 1A), subjects III:3 and IV:2 with hear-
ing loss had a unique heterozygous missense mutation
of ACTG1 (c.802G >A; p.G268S), whereas subject III:4
with normal hearing did not. ACTG1 encodes actin gamma
1 and is responsible for DFNA20/26 (OMIM 604717) [28].
The glycine residue at 268 of actin gamma 1 is located
on a hydrophobic loop that has been suggested to be
critical for polymerization of the actin monomers into
a filament (Figures 2A and 2B) [29]. Molecular model-
ing predicted that the p.G268S mutation would dis-
rupt the hydrophobic interactions that are important
for polymerization of actin gamma 1 (Figures 2C and
Figure 2D). The p.G268S mutant would weaken poly-
merization of actin gamma 1, which could result in
destabilized cytoskeletal structure of stereocilia and
dysfunction of the sensory hair cells.
Family 2 (Figure 1B) had two candidate genes with
possible pathogenic mutations: A unique heterozygous
POU4F3 frameshift mutation, c.1007delC (p.A336Vfs),
was detected in subjects III:1 and IV:3 with hearing loss,
and a unique heterozygous DFNA5 nonsense mutation,
c.781C >T (p.R261X), was detected in subjects III:2 and
IV:3 with hearing loss, whereas subject IV:1 with normal
hearing had neither of these mutations. Sanger sequen-
cing revealed that subject IV:2 with hearing loss had
both the heterozygous mutations. POU4F3 is responsible
for DFNA15 (OMIM 602459) [30,31], and DFNA5 isresponsible for DFNA5 (OMIM 600994) [32]. A frame-
shift mutation in DFNA5, which would lead to decreased
expression, has been reported not to cause hearing loss
[33]; therefore, the cause of hearing loss in subjects IV:2
and IV:3 is more likely to POU4F3 with the p.A336Vfs
mutation derived from subject III:1, rather than DFNA5
with p.R261X mutation derived from subject III:2.
In family 3 (Figure 1C), subjects III:1 and III:2 with
hearing loss had compound heterozygous SLC26A5 with
c.209G >A (p.W70X) and c.390A >C (p.R130S) muta-
tions, whereas subjects II:1 and II:2 with normal hearing
had a heterozygous p.W70X mutation and a heterozy-
gous p.R130S mutation, respectively. SLC26A5 encodes
prestin, a member of the SLC26A/SulP transporter family,
and is responsible for DFNB61 (OMIM 613865) [34].
In family 4 (Figure 1D), subjects I:2 and II:1 with
hearing loss did not have candidate mutations in the
first 61 genes. Analysis of the additional 23 genes indi-
cated a heterozygous SIX1 mutation, c.328C >T (p.R110W),
in the subjects with hearing loss but not in subject I:1 with
normal hearing. SIX1 is responsible for DFNA23 (OMIM
605192) and Branchio-otic syndrome 3 (BOS3, OMIM
608389). The p.R110W mutation was previously reported
in two BOS3 families [35]. To make the clinical diagnosis
of branchiootorenal syndrome or branchiootic syndrome,
major and minor criteria of these syndromes must be
present [36]. In the affected subjects of the present
study, clinical histories were thoroughly evaluated and
physical examination of the ear, nose, throat, head and
neck, and audiological tests were performed. In addition,
CT of the temporal bone was evaluated in subject II:1.
With these examinations, the affected subjects did not
Table 2 Summary of the number of variants detected in each subject
Family Subject Number of genes analyzed No.SNV/MNV* No. non-synonymous SNV/MNV
1
III:3 61 414 84
III:4 61 370 74
IV:2 61 391 82
2
III:1 61 386 81
III:2 61 422 87
IV:1 61 435 82
IV:3 61 400 84
3
II:1 61 383 82
II:2 61 339 70
III:1 61 350 74
III:2 61 398 86
4
I:1 84 570 138
I:2 84 569 126
II:1 84 546 131
5
II:2 61 388 72
II:4 61 374 87
III:1 61 361 84
III:2 61 396 85
6
I:1 61 429 96
I:2 61 371 81
II:1 61 378 86
II:2 61 375 84
7
I:1 84 607 139
I:2 84 554 126
II:2 84 582 132
II:1 84 539 117
*SNV, single nucleotide variant; MNV, multiple nucleotide variant.
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other than hearing loss. Therefore, family 4 was consid-
ered to have non-syndromic hearing loss, DFNA23, based
on the clinical information available at the time of this
study.
In family 5 (Figure 1E), subjects III:1 and III:2 with
hearing loss had compound heterozygous MYO7A
mutations, c.6439-2A >G (intron 51) and c.6478T >G
(p.W2160G). Subjects II:2 and II:4 with normal hear-
ing had a heterozygous c.6439-2A >G mutation and a
heterozygous p.W2160G mutation, respectively. MYO7A
is responsible for DFNA11 (OMIM 601317) [37], DFNB2
(OMIM 600060) [38], and Usher syndrome 1B (OMIM
276900) [39]. Tryptophan 2160 in myosin 7A was found
to be located in a carboxyl-terminal FERM domain in
the myosin-tail (Figures 3A and Figure 3B); this domain
reportedly associates with filamentous actin [40] and
contributes to hair bundle formation. Molecular modeling
predicted that the p.W2160G mutation would reduce
hydrophobic interactions among residues in the center ofthe F3 subdomain of the FERM domain (Figures 3C and
3D). The p.W2160G mutation would destabilize the
structure of the F3 domain and could result in disrupted
protein interaction and stereocilial degeneration of the
sensory hair cells [41,42].
In family 6 (Figure 1F), subjects II:1 and II:2 with
hearing loss had a heterozygous CDH23 mutation,
c.719C>T (p.P240L), and a heterozygous PCDH15 muta-
tion, c.848G >A (p.R283H). Sanger sequencing revealed
that the other subject with hearing loss (subject II:3) also
had both heterozygous CDH23 and PCDH15 mutations.
A p.P240L mutation inCDH23 has been reported to be
pathogenic [43]. Subject I:1 with normal hearing had a
heterozygous mutation in CDH23 (p.P240L), and subject
I:2 with normal hearing had a heterozygous mutation in
PCDH15 (p.R283H). CDH23 is responsible for both
DFNB12 (OMIM 601386) and Usher syndrome 1D (OMIM
601067) [44], whereas PCDH15 is responsible for both
DFNB23 (OMIM 609533) and Usher syndrome 1F (OMIM
602083) [45]. Double heterozygous mutations of CDH23
Table 3 Summary of possible pathogenic mutations
Gene Nucleotidechange
Amino acid





















POU4F3 c.1007delC p.A336Vfs NM_002700.2 None - 0 0/192 - - Possible 2
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Table 4 Summary of variants with uncertain pathogenicity
Gene Nucleotidechange
Amino acid















DFNA5 c.781C>T p.R261X NM_004403.2 None - 0 0/192 - - Uncertain 2
























Figure 2 Molecular modeling of ACTG containing the p.G268S mutation. (A) Ribbon model of filamentous actin gamma 1. (B) Magnified
ribbon model of filamentous actin gamma 1. Glycine residue 268 is shown in red and indicated by an arrow. Regions in yellow and green
indicate the hydrophobic loop (262–274; a) and the corresponding interactive residues (281–289; b), respectively. (C and D) Vertical views of the
regions a and b superimposed with predicted surface hydrophobicity in the wild type (C) and the p.G268S mutant (D).
Figure 3 Molecular modeling of MYO7A containing the p.W2160G mutation. (A) Structural motif of myosin 7A. Tryptophan 2160 on the
C-terminal 4.1 protein-ezrin-radixin-moesin (FERM) domain is indicated by an arrow. Motor, myosin motor domain; IQ, Isoleucine-glutamine
calmodulin-binding motif; CC, coiled-coil domain; MyTH4, myosin tail homology 4 domain; SH3, Src homology 3 domain. (B) Ribbon model
of the C-terminal FERM domain consisting of three subdomains (F1, F2, F3) and an MyTH4 domain. (C, D) Magnified ribbon model of the F3
subdomain superimposed with predicted surface hydrophobicity in the wild type (C) and the p.W2160G mutant (D).
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of hearing loss [46].
In family 7 (Figure 1G), subjects II:1 and II:2 with
hearing loss did not have candidate mutations in the first
61 genes. Analysis of the additional 23 genes indicated
a compound heterozygous USH2A variant or mutation,
c.1346G >A(p.R449H) and c.12431delC (p.A4144GfsX23),
in subjects with hearing loss, whereas subjects I:1 and II:2
with normal hearing had a heterozygous p.R449H variant
and a heterozygous p.A4144GfsX23 mutation, respect-
ively. USH2A is responsible for Usher syndrome 2A
(OMIM 276901) [47]. Although USH2A with the p.R449H
variant was not found on dbSNP135, 1000GENOME, or
the Exome Variant Server, the allele frequency in Japanese
control subjects with normal hearing was 1.3% (5/378).
In the remaining eight families, none of the detected
variants co-segregated with hearing loss in the pedigrees
(data not shown).
Discussion
In the present study we selected Japanese subjects that
had hereditary hearing loss without GJB2 mutations,
mitochondrial mutations, enlarged vestibular aqueduct
or auditory neuropathy-associated OTOF mutations, and
we aimed to detect the spectrum of rare deafness genes
in these patients. Targeted NGS for 84 deafness genes
resulted in identification of candidate genes in 7 of 15
families and revealed the diverse spectrum of rare deaf-
ness genes in Japanese subjects with nonsyndromic hear-
ing loss for the first time. This is the first report of
mutations in ACTG1, POU4F3, and SLC26A5 in Japanese
families with hearing loss. Families 5, 6, and 7 appeared to
have candidate mutations or variants in MYO7A, CDH23,
PCDH15, and USH2A, all of which are associated with
Usher syndrome [39,44,45,47]. Our results are in contrast
to an NGS study of a different ethnic group [48], which
showed TMC1 mutations to be the prevalent candidate
cause of hearing loss.
For the eight families without candidate genes, hearing
loss could be attributable to mutations in non-captured
regions including regulatory domains of the 84 genes,
other unidentified deafness genes, unknown multigenic
causes, copy number variations, or chromosomal struc-
tural change.
Double heterozygous mutations
In family 5, double heterozygous mutations of CDH23
and PCDH15 were detected as a candidate cause. This
combination of double heterozygous mutations has been
reported [46]. Cadherin 23 and protocadherin 15 consist
of the upper and lower part of tip link, respectively,
which is critical for proper function of mechanotransduc-
tion channels on the stereocilia of the sensory hair cells
[49]. In addition, P240 of CDH23 is on the extracellularcadherin 1 domain, and R283 of PCDH15 is on the extra-
cellular cadherin 2 domain, which are considered to inter-
act with each other for tip-link bound [49], raising the
possibility that the double heterozygous mutations could
lead to a destabilized tip-link.
Additional findings of double heterozygous mutations
associated with hereditary hearing loss have been reported
for KCNJ10 and SLC26A4 [50] and for FOXI1 and
SLC26A4 [51], and some mutated genes may have a
modifying effect [52]. Although most NGS pipelines, in-
cluding ours, focus on identifying monogenic causes of
disease, development of a detection strategy for digenic
and oligogenic causes of disease should be considered in
the future.
Discrimination of mutations from variants
The key challenge for the diagnostic application of NGS is
to distinguish causal alleles from the numerous nonpatho-
genic variants present in each individual. In the present
study, for example, the high allele frequency of USH2A
with the p.R449H variant in Japanese control subjects im-
plied that pathogenicity of this variant was unlikely. Ethnic
diversity of genetic variance has been reported in deafness
genes such as OTOF [12] and CDH23 [43,53], and integra-
tion of a database of genetic variants with allele frequen-
cies in a specific ethnic group would increase the certainty
of the causative nature of genetic mutations by filtering
out variants that occur with high frequency. This would
facilitate targeted NGS analysis for genetic diagnosis of
hearing loss.
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Additional file 1: The 84 genes that were targeted for next-
generation sequencing.
Additional file 2: Clinical features of family members.
Additional file 3: Audiograms of subjects with hearing loss in the
seven families in which candidate genes were detected. Figure
legend: Hearing level as a function of frequency in subject IV:2 from
family 1 (A), subject III:3 from family 1 (B), subject IV:3 from family 2 (C),
subject III:1 from family 2 (D), subject III:2 from family 2 (E), subject III:1
from family 3 (F), subject II:1 from family 4 (G), subject III:1 from family 5
(H), subject II:2 from family 6 (I), subject II:3 from family 6 (J), and subject
II:2 from family 7 (K). Open circles with solid lines represent air
conduction thresholds of the right ear; crosses with dotted lines
represent air conduction thresholds of the left ear; [ symbols represent
bone conduction thresholds of the right ear; ] symbols represent bone
conduction thresholds of the left ear; arrows pointing to the bottom left
represent scale-out hearing level of the right ear; arrows pointing to the
bottom right represent scale-out hearing level of the left ear.
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